Table 2.
Baseline characteristic Of PAH-Patients and controls
| PAH cohort 1 (n = 92) | PAH cohort 2 (n = 15) | Diseased controls (n = 39) | Healthy controls (n = 14) | |
|---|---|---|---|---|
| Age (years) |
57 (48–69) |
58 (49–65) |
53 (37–71) |
39 (27–53) |
| Gender (female%) |
66 |
62 |
68 |
29 |
| 6MWD [m] |
335 (248–427) |
352 (295–413) |
389 (280–510) |
|
| NYHA class [%] |
|
|
|
|
| I |
0 |
0 |
40 |
|
| II |
24 |
20 |
42 |
|
| III |
71 |
67 |
18 |
|
| IV |
5 |
13 |
0 |
|
| Edema [%] |
39 |
45 |
14 |
|
| S-Na [mmol/l] |
139 (137–142) |
140 (138–141) |
142 (139–144) |
|
| Creatinine [μg/l] |
83 (67–95) |
85 (73–98) |
79 (67–93) |
|
| eGFR (CKD-EPI) [ml/min] |
83 (68–98) |
103 (79–99) |
89.4 (72–118) |
|
| NT-proBNP [pg/ml] |
2125 (588–3225) |
2063 (990–2466) |
474 (80–698) |
|
| Copeptin [pmol/l] |
20.1 (7–25) |
24.5 (8–37) |
5.1 (2–7) |
1.8 (1.4 -2.2) |
| RA [mmHg] |
6.1 (4–9) |
7.7 (5–8) |
1.9 (2.5) |
|
| PCWP [mmHg] |
8.6 (5–11) |
7.9 (4–9) |
7.8 (3.0) |
|
| mPAP [mmHg] |
46 (37–54) |
49 (43–56) |
17.6 (12–23) |
|
| CI [ml/min/m2] |
2.4 (1.8-2.8) |
1.9 (1.6-2.5) |
2.6 (2.3-2.8) |
|
| PVR [dyn · sec · cm-5] |
792 (469–1024) |
1004 (696–1325) |
191 (120–271) |
|
| SvO2 [%] |
63.1 (57–70) |
61.2 (56–68) |
72 (67–77) |
|
| Diagnosis [%] |
|
|
|
|
| IPAH |
64 |
63 |
- |
|
| PAH associated with Congenital heart disease |
11 |
7 |
- |
|
| PAH associated with Connective tissue disease | 25 | 30 | - |
Shown are baseline data from PAH cohort 1, cohort 2 as well as diseased and healthy controls.
Except for sex, NYHA class, edema and diagnosis (%), data are shown as median (interquartile range, IQR).
Definition of abbreviations: 6MWD 6 minute walking distance, NYHA New York Heart Association, S-Na Serum Sodium concentration, eGFR (CKD-EPI) estimated glomerular filtration calculated according the Chronic Kidney Disease Epidemiology Collaboration formula, NT-proBNP N-terminal prohormone of brain natriuretic peptide, RA right atrial pressure, PCWP pulmonary capillary wedge pressure, mPAP mean pulmonary artery pressure, CI cardiac index, PVR pulmonary vascular resistance, SvO2 mixed venous oxygen saturation, IPAH idiopathic pulmonary arterial hypertension.